JP2015514771A5 - - Google Patents

Download PDF

Info

Publication number
JP2015514771A5
JP2015514771A5 JP2015507143A JP2015507143A JP2015514771A5 JP 2015514771 A5 JP2015514771 A5 JP 2015514771A5 JP 2015507143 A JP2015507143 A JP 2015507143A JP 2015507143 A JP2015507143 A JP 2015507143A JP 2015514771 A5 JP2015514771 A5 JP 2015514771A5
Authority
JP
Japan
Prior art keywords
polyarginine peptide
polyarginine
composition
cysteines
item
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2015507143A
Other languages
English (en)
Japanese (ja)
Other versions
JP2015514771A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2013/036938 external-priority patent/WO2013158739A1/en
Publication of JP2015514771A publication Critical patent/JP2015514771A/ja
Publication of JP2015514771A5 publication Critical patent/JP2015514771A5/ja
Pending legal-status Critical Current

Links

JP2015507143A 2012-04-17 2013-04-17 神経保護性組成物および使用方法 Pending JP2015514771A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261625349P 2012-04-17 2012-04-17
US61/625,349 2012-04-17
PCT/US2013/036938 WO2013158739A1 (en) 2012-04-17 2013-04-17 Neuroprotective composition and method of use

Publications (2)

Publication Number Publication Date
JP2015514771A JP2015514771A (ja) 2015-05-21
JP2015514771A5 true JP2015514771A5 (cg-RX-API-DMAC7.html) 2016-06-16

Family

ID=49384027

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2015507143A Pending JP2015514771A (ja) 2012-04-17 2013-04-17 神経保護性組成物および使用方法

Country Status (6)

Country Link
US (2) US20150126457A1 (cg-RX-API-DMAC7.html)
EP (1) EP2872160A4 (cg-RX-API-DMAC7.html)
JP (1) JP2015514771A (cg-RX-API-DMAC7.html)
AU (1) AU2013249337A1 (cg-RX-API-DMAC7.html)
CA (1) CA2870711A1 (cg-RX-API-DMAC7.html)
WO (1) WO2013158739A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2872160A4 (en) 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD
WO2015061856A1 (en) 2013-10-30 2015-05-07 University Of Western Australia Neuroprotective peptides
US20170114093A1 (en) * 2015-05-29 2017-04-27 Andrew Peter Mallon Methods of Treatment and Prevention of Disease by Arginine-rich Compositions that Induce Cytoprotection and Neuroprotection
US20210101935A1 (en) 2019-10-02 2021-04-08 Brown University Cyclic peptidomimetic for the treatment of neurological disorders

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20010012809A (ko) * 1997-05-21 2001-02-26 더 보드 오브 트러스티스 오브 더 리랜드 스탠포드 쥬니어 유니버시티 생체막을 통한 수송을 증진시키는 조성물 및 방법
US7229961B2 (en) * 1999-08-24 2007-06-12 Cellgate, Inc. Compositions and methods for enhancing drug delivery across and into ocular tissues
WO2005084301A2 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
WO2009029678A1 (en) * 2007-08-27 2009-03-05 Kai Pharmaceuticals, Inc. PROTEIN KINASE C-δ INHIBITORS THAT PROTECT AGAINST CELLULAR INJURY AND INFLAMMATION AND PROMOTE ASTROCYTE PROLIFERATION
WO2010150708A1 (ja) * 2009-06-22 2010-12-29 株式会社メディネット 蛋白質の修飾剤
MX2012001213A (es) * 2009-07-29 2012-06-12 Kai Pharmaceuticals Inc Agentes terapeuticos para reducir los niveles de la hormona paratiroidea.
US20110053829A1 (en) * 2009-09-03 2011-03-03 Curevac Gmbh Disulfide-linked polyethyleneglycol/peptide conjugates for the transfection of nucleic acids
EP2872160A4 (en) 2012-04-17 2015-11-25 Univ Brown NERVO-PROTECTING COMPOSITION AND USE METHOD

Similar Documents

Publication Publication Date Title
JP2016519128A5 (cg-RX-API-DMAC7.html)
MX2017004592A (es) Formulaciones farmaceuticas para la administracion oral de farmacos peptidicos o proteinicos.
RU2015147876A (ru) Пероральная дозированная форма соединений глюкагоноподобного пептида-1
WO2015183963A3 (en) Therapeutic compositions including redox-active parabenzoquinones and uses thereof
JP2016532722A5 (cg-RX-API-DMAC7.html)
EP1626055A3 (en) Non-mammalian GnRH analogs and uses thereof in the regulation of the immune system
JP2013542919A5 (cg-RX-API-DMAC7.html)
CN102209553A (zh) 肽制剂及其应用
WO2016004093A3 (en) Therapeutic compositions including galectin-3 inhibitors and uses thereof
RU2012140704A (ru) Способ профилактики и/или лечения фиброза и/или помутнения роговицы (варианты), способ получения фармацевтической композиции для профилактики и/или лечения фиброза и/или помутнения роговицы и глазная фармацевтическая композиция
JP2012501973A5 (cg-RX-API-DMAC7.html)
JP2012115277A5 (cg-RX-API-DMAC7.html)
JP2013504318A5 (cg-RX-API-DMAC7.html)
JP2019529541A5 (cg-RX-API-DMAC7.html)
UA107578C2 (uk) Комбінована терапія при лікуванні діабету
JP2015514771A5 (cg-RX-API-DMAC7.html)
JP2019533722A5 (cg-RX-API-DMAC7.html)
FI3511004T3 (fi) Yhdistelmävalmisteita syövän hoitoon
JP2017503014A5 (cg-RX-API-DMAC7.html)
JP2019513752A5 (cg-RX-API-DMAC7.html)
RU2015110114A (ru) Ангиотензин в лечении состояний головного мозга
WO2012090225A3 (en) Novel cocrystals / molecular salts of metformin with oleoylethanolamide as an effective anti-diabetic + anti- obesity agent
JP2015513544A5 (cg-RX-API-DMAC7.html)
WO2020099925A3 (en) Peptides and pharmaceutical compositions for treating eye diseases
HK1249011A1 (zh) 包括线粒体分裂抑制肽的治疗组合物、其变体及这些的使用方法